Administration Seeks to Modernize Vaccine Production - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Administration Seeks to Modernize Vaccine Production
President Obama and HHS eye innovation and countermeasures to protect public health.

Pharmaceutical Technology
Volume 10, Issue 34, pp. 32-38

Innovation Sherpas

HHS also proposes establishing "Sherpa" teams of government, academic, and industry experts to guide discoverers of promising MCM candidates through the R&D and regulatory processes. National Institutes of Health (NIH) experts provide less experienced researchers with information on preclinical services and clinical-trial support, but the Sherpa teams would offer a more formal effort, explained Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, at the press briefing.

Probably the most problematic HHS proposal is the provision of $200 million to establish an independent, nonprofit investment entity to fund small innovative firms that are developing novel biodefense technologies. Instead of funding research on specific products, the MCM Strategic Investor would invest in companies, provided Congress authorizes such a plan, which would give money to industry. A priority is to support firms developing new antimicrobials to combat multidrug-resistant organisms, which are spreading globally. The initiative also would fund research on host pathways used by multiple agents of disease, and develop flexible platform technologies for diagnostics, vaccines, and therapeutics.

HHS hopes to support MCM development by better coordinating and integrating its R&D programs internally and with other federal agencies. An efficient and flexible contracting process would encourage private-sector investment, as would a five-year budget and planning process. In addition, Sebelius plans to review current liability protections for private-sector MCM developers to determine whether stronger safeguards are needed to spur product development and manufacture. Lurie emphasizes that the $2-billion program is not "simply a cash infusion to industry." Rather, by eliminating technical and regulatory barriers, the project will reduce the risk for companies that invest their own resources in vaccines and MCMs.

For the upcoming influenza season, the Centers for Disease Control and Prevention hope to vaccinate 160 million Americans with a three-strain influenza vaccine in expectation that H1N1 will return, along with seasonal influenza. The need to produce only one influenza vaccine should avoid many of the problems that occurred in 2009. Yet, a quiet influenza season also could diminish interest on Capitol Hill in increasing spending on countermeasure research and vaccine development and in finding better ways to protect against biological threats.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here